Simental LLG, Silva FR, Gómez MGA, Pérez JF

Idioma: Español
Referencias bibliográficas: 20
Paginas: 1-7
Archivo PDF: 455.25 Kb.

RESUMEN

Antecedentes: El linfoma difuso de células grandes B tipo pierna pertenece a un grupo de linfomas no Hodgkin que afectan la piel sin evidencia de enfermedad extracutánea al diagnóstico; representa el 4% de todos los casos de linfomas cutáneos.
Caso clínico: Paciente femenina de 70 años con una tumoración única en el miembro pélvico derecho, que recibió tratamiento con quimioterapia y radioterapia.
Conclusiones: El linfoma difuso de células grandes B tipo pierna se considera un linfoma agresivo, con supervivencia a 5 años menor al 60%. El tratamiento se basa en quimioterapia sistémica con o sin radioterapia y el pronóstico es peor en comparación con el de otros linfomas cutáneos.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Kabashima K. Immunology of the skin: Basic and clinicalsciences in skin immune responses [Internet]. Springer; 2016.

2. Grange F, Beylot-Barry M, Courville P, Maubec E, et al.Primary cutaneous diffuse large B-cell lymphoma, legtype: clinicopathologic features and prognostic analysisin 60 cases. Arch Dermatol 2007; 143 (9): 1144-50. http://dx.doi.org/10.1001/archderm.143.9.1144

3. Willemze R, Cerroni L, Kempf W, Berti E, et al. The 2018update of the WHO-EORTC classification for primary cutaneouslymphomas. Blood 2019; 133 (16): 1703-14. http://dx.doi.org/10.1182/blood-2018-11-881268

4. Cerroni L. Past, present and future of cutaneous lymphomas.Semin Diagn Pathol 2017; 34 (1): 3-14. http://dx.doi.org/10.1053/j.semdp.2016.11.001

5. Hristov AC. Primary cutaneous diffuse large B-cell lymphoma,leg type: diagnostic considerations. Arch Pathol LabMed 2012; 136 (8): 876-81. http://dx.doi.org/10.5858/arpa.2012-0195-RA

6. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classificationfor cutaneous lymphomas. Blood 2005; 105 (10):3768-3785. http://doi.org.10.1182/blood-2004-09-3502

7. Vitiello P, Sica A, Ronchi A, Caccavale S, et al. Primary cutaneousB-cell lymphomas: An update. Front Oncol 2020; 10:651. http://dx.doi.org/10.3389/fonc.2020.00651

8. Hope CB, Pincus LB. Primary cutaneous B-cell lymphomas.Clin Lab Med 2017; 37 (3): 547-74. http://dx.doi.org/10.1016/j.cll.2017.05.009

9. Koens L, Zoutman WH, Ngarmlertsirichai P, Przybylski GK, etal. Nuclear factor-κB pathway-activating gene aberranciesin primary cutaneous large B-cell lymphoma, leg type.J Invest Dermatol 2014; 134 (1): 290-2. http://dx.doi.org/10.1038/jid.2013.265

10. Pham-Ledard A, Prochazkova-Carlotti M, Andrique L,Cappellen D, et al. Multiple genetic alterations in primarycutaneous large B-cell lymphoma, leg type support a commonlymphomagenesis with activated B-cell-like diffuselarge B-cell lymphoma. Mod Pathol 2014; 27 (3): 402-11.http://dx.doi.org/10.1038/modpathol.2013.156

11. Senff NJ, Hoefnagel JJ, Jansen PM, Vermeer MH, et al. Reclassificationof 300 primary cutaneous B-cell lymphomas accordingto the new WHO-EORTC classification for cutaneouslymphomas: comparison with previous classifications andidentification of prognostic markers. J Clin Oncol 2007; 25(12): 1581-7. http://dx.doi.org/10.1200/JCO.2006.09.6396

12. Senff NJ, Noordijk EM, Kim YH, Bagot M, et al. EuropeanOrganization for Research and Treatment of Cancer andInternational Society for Cutaneous Lymphoma consensusrecommendations for the management of cutaneous B-celllymphomas. Blood 2008; 112 (5): 1600-9. http://dx.doi.org/10.1182/blood-2008-04-1528501

13. Hamilton SN, Wai ES, Tan K, Alexander C, et al. Treatmentand outcomes in patients with primary cutaneous B-celllymphoma: the BC Cancer Agency experience. Int J RadiatOncol Biol Phys 2013; 87 (4): 719–25. http://dx.doi.org/10.1016/j.ijrobp.2013.07.019

14. Gupta E, Accurso J, Sluzevich J, Menke DM, Tun HW. Excellentoutcome of immunomodulation or Bruton’s tyrosinekinase inhibition in highly refractory primary cutaneousdiffuse large B-cell lymphoma, leg type. Rare Tumors 2015;7 (4): 6067. http://dx.doi.org/10.4081/rt.2015.6067

15. Johannes B, Stephanie E, Anca S, Stefan S, et al. Ibrutinibcan induce complete remissions and sustained responsesin refractory cutaneous or leg-type diffuse large B-celllymphoma. Blood 2018; 132 (Supplement 1): 4237. https://doi.org/10.1182/blood-2018-99-117032

16. Kater AP, Seymour JF, Hillmen P, Eichhorst B, et al. Fixedduration of venetoclax-rituximab in relapsed/refractorychronic lymphocytic leukemia eradicates minimal residualdisease and prolongs survival: post-treatment follow-upof the MURANO phase III study. J Clin Oncol 2019; 37 (4):269-77. http://dx.doi.org/10.1200/JCO.18.01580

17. Khan N, Kahl B. Targeting BCL-2 in hematologic malignancies.Target Oncol 2018; 13 (3): 257-67. http://dx.doi.org/10.1007/s11523-018-0560-7

18. Advani R, Forero-Torres A, Furman RR, Rosenblatt JD, etal. Phase I study of the humanized anti-CD40 monoclonalantibody dacetuzumab in refractory or recurrent non-Hodgkin’s lymphoma. J Clin Oncol 2009; 27 (26): 4371-7.http://dx.doi.org/10.1200/JCO.2008.21.3017

19. Zhou XA, Louissaint A Jr, Wenzel A, Yang J, et al. Genomicanalyses identify recurrent alterations in immune evasiongenes in diffuse large B-cell lymphoma, leg type. JInvest Dermatol 2018; 138 (11): 2365-76. http://dx.doi.org/10.1016/j.jid.2018.04.038

20. Kraft RM, Ansell SM, Villasboas JC, Bennani NN, et al.Outcomes in primary cutaneous diffuse large B-cell lymphoma,leg type. Hematol Oncol 2021; 39 (5): 658 63.http://dx.doi.org/10.1002/hon.2919